Antivirulence Therapeutics Market Report 2026

Antivirulence Therapeutics Market Overview

• Antivirulence Therapeutics market size has reached to $1.45 billion in 2025 • Expected to grow to $3.04 billion in 2030 at a compound annual growth rate (CAGR) of 16% • Growth Driver: The Increasing Prevalence Of Hospital-Acquired Infections Driving The Growth Of The Market Due To Poor Infection Control Practices • Market Trend: Progress In Toxin-Targeting Clinical Research Offers New Approach To Combat Severe Bacterial Infections • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Antivirulence Therapeutics Market?

Antivirulence therapeutics refer to a class of treatments that target and neutralize the virulence factors of pathogens, rather than killing or inhibiting their growth directly. These therapies work by disarming the disease-causing mechanisms of microbes, thereby reducing their ability to cause infection and allowing the host immune system to clear them more effectively. The main product types of antivirulence therapeutics include small molecule inhibitors, monoclonal antibodies, peptides, and other product types. Small molecule inhibitors refer to low molecular weight compounds designed to block virulence factors of pathogens without directly killing them, thereby reducing resistance development. These products are categorized by pathogen type including bacterial, viral, fungal, and other pathogen types and are administered through oral, injectable, and other route of administrations. They are used in applications such as hospital acquired infections, community acquired infections, and others, and are utilized by end users including hospitals, clinics, research institutes, and others.

What Is The Antivirulence Therapeutics Market Growth Forecast?

The antivirulence therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.04 billion in 2030 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to rising demand for alternative non-antibiotic therapies, increasing adoption of precision infectious disease treatments, expansion of antimicrobial stewardship programs, growth in bacteriophage and biologics-based therapeutics, advancement in AI-based pathogen and virulence modeling technologies. Major trends in the forecast period include precision medicine approaches for targeted antivirulence drug design, cloud-based genomic and pathogen data integration for infectious disease research, iot-enabled real-time infection surveillance and outbreak tracking systems, industry 4.0 enabled automated antimicrobial and antivirulence compound screening platforms, increasing shift toward non-bactericidal therapeutic strategies to reduce antimicrobial resistance.

Global Antivirulence Therapeutics Market Segmentation

1) By Product Type: Small Molecule Inhibitors, Monoclonal Antibodies, Peptides, Other Product Types 2) By Pathogen Type: Bacterial, Viral, Fungal, Other Pathogen Types 3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration 4) By Application: Hospital Acquired Infections, Community Acquired Infections, Other Applications 5) By End User: Hospitals, Clinics, Research Institutes, Other End Users Subsegments: 1) By Small Molecule Inhibitors: Quorum Sensing Inhibitors, Toxin Production Inhibitors, Biofilm Formation Inhibitors, Secretion System Inhibitors, Adhesion Inhibitors, Enzyme Activity Inhibitors 2) By Monoclonal Antibodies: Toxin Neutralizing Antibodies, Surface Protein Targeting Antibodies, Adhesion Blocking Antibodies, Immune Modulating Antibodies, Pathogen Specific Antibodies, Virulence Factor Targeting Antibodies 3) By Peptides: Antimicrobial Peptides, Anti Biofilm Peptides, Host Defense Peptides, Membrane Disrupting Peptides, Virulence Suppressing Peptides, Synthetic Therapeutic Peptides 4) By Other Product Types: Bacteriophage Therapies, Endolysin Therapies, Antisense Oligonucleotide Therapies, Engineered Protein Therapeutics, Nanoparticle Based Therapeutics, Microbiome Based Therapeutics

What Are The Drivers Of The Antivirulence Therapeutics Market?

The increasing prevalence of hospital-acquired infections is expected to propel the growth of the antivirulence therapeutics market going forward. Hospital-acquired infections (HAIs) refer to infections that a patient develops while receiving medical treatment in a healthcare facility, which were not present or incubating at the time of admission. Increasing prevalence of hospital-acquired infections is due to poor infection control practices such as inadequate hand hygiene, improper sterilization of medical equipment, and non-compliance with standard safety protocols, which facilitate the spread of pathogens within healthcare settings. Antivirulence therapeutics attenuates hospital-acquired infections by disrupting bacterial virulence mechanisms such as toxin production, adhesion, and quorum sensing, thereby lowering pathogen pathogenicity and disease severity without killing the bacteria and helping reduce the emergence of antimicrobial resistance. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022–23, hospital-acquired complications (HACs) occurred in 115,000 public hospitalizations (2.0%) and 34,200 private hospitalizations (0.8%). The most frequent complication was healthcare-associated infection (37%), followed by delirium (13%) and cardiac complications (12%). Therefore, the increasing prevalence of hospital-acquired infections is expected to propel the growth of the antivirulence therapeutics industry. The rising antimicrobial resistance is expected to propel the growth of the antivirulence therapeutics market going forward. Antimicrobial resistance (AMR) refers to the ability of microorganisms such as bacteria, viruses, fungi, and parasites to withstand the effects of medicines that were previously effective in treating infections caused by them. Rising antimicrobial resistance is due to the excessive and inappropriate use of antibiotics in humans and livestock, which accelerates the survival and spread of drug-resistant microorganisms. Antivirulence therapeutics reduce the selective pressure that drives antimicrobial resistance by targeting bacterial virulence mechanisms rather than killing pathogens directly, thereby limiting the emergence and spread of resistant strains. For instance, in November 2025, according to the UK Health Security Agency, a UK-based government agency The burden of antimicrobial resistance (AMR), measured by population-level incidence of antibiotic-resistant infections in key public health organisms, rose by 9.3% compared with 2023 levels. Therefore, the rising antimicrobial resistance is expected to propel the growth of the antivirulence therapeutics industry.

Key Players In The Global Antivirulence Therapeutics Market

Major companies operating in the antivirulence therapeutics market are GSK plc, Shionogi & Co. Ltd., AstraZeneca, Bicycle Therapeutics plc, BiomX Inc., PHAXIAM Therapeutics S.A., Armata Pharmaceuticals Inc., Eligo Bioscience SAS, LimmaTech Biologics AG, Aurobac Therapeutics SAS, Micreos Pharmaceuticals AG, Locus Biosciences, BioVersys GmbH, Phagelux Inc., Intralytix Inc., Clarametyx Biosciences, Precisio Biotix Therapeutics Inc., Microbiotix Inc., Red Queen Therapeutics, Technophage S.A., NanoViricides Inc., Inhalon Biopharma, Centauri Therapeutics

Global Antivirulence Therapeutics Market Trends and Insights

Major companies operating in the antivirulence therapeutics market are focusing on advancing clinical trials to develop innovative solutions, such as toxin-neutralizing anti-virulence agents to inhibit bacterial pathogenic mechanisms without killing the microbes, thereby reducing disease severity and limiting antimicrobial resistance. Toxin-neutralizing anti-virulence agents are therapeutic compounds that target and inactivate bacterial toxins or virulence factors rather than killing the bacteria, thereby reducing their ability to cause disease while minimizing the risk of antimicrobial resistance. For instance, in November 2023, Eagle Pharmaceuticals Inc., a US-based pharmaceutical company, announced the presentation of its ongoing CAL02 Phase 2 clinical trial progress at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. The investigational therapy CAL02 is designed as an anti-virulence treatment that neutralizes bacterial toxins rather than directly killing bacteria, aiming to reduce disease severity and complement existing antibiotic therapies. This development highlights the company’s focus on addressing antimicrobial resistance by advancing novel adjunctive treatment approaches for severe bacterial infections such as community-acquired pneumonia.

Regional Outlook

North America was the largest region in the antivirulence therepeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antivirulence Therapeutics Market?

The antivirulence therapeutics market consists of sales of bacteriophage-based therapies, nucleic acid-based therapies, anti-toxin and immune-modulating biologics, and host-directed therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antivirulence Therapeutics Market Report 2026?

The antivirulence therapeutics market research report is one of a series of new reports from The Business Research Company that provides antivirulence therapeutics market statistics, including antivirulence therapeutics industry global market size, regional shares, competitors with a antivirulence therapeutics market share, detailed antivirulence therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antivirulence therapeutics industry. This antivirulence therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.